Zacks Small Cap Analysis – COCP: CC-42344 Reveals In Vitro Exercise In opposition to Avian Influenza A (H5N1)… – Cyber Information
By David Bautz, PhD NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT Enterprise Replace CC-42344 Reveals In Vitro Exercise In opposition to Avian Influenza H5N1 PB2 Protein On June 20, 2024, Cocrystal Pharma, Inc. (NASDAQ:COCP) introduced that its broad-spectrum antiviral compound CC-43244 inhibits the exercise of the avian influenza A (H5N1) PB2 protein in a pressure … Read more